United Therapeutics Wins Unituxin Approval, Pediatric Priority Review Voucher – With NIH Support
This article was originally published in The Pink Sheet Daily
The National Cancer Institute conducted the clinical trials of Unituxin for treatment of pediatric high-risk neuroblastoma and teamed with United for manufacturing and commercialization.
You may also be interested in...
With partner Genentech, AbbVie is planning to file the BCL-2 inhibitor for US and EU approval in tough-to-treat CLL later this year on the back of promising Phase II data.
Priority review ticket might be used on Type 2 diabetes combo LixiLan, expected to be filed later this year.
Merck & Co has gained its first positive opinion for Keytruda from Europe’s top advisory panel the CHMP, while Bristol-Myers Squibb’s Opdivo has received its second positive opinion, for use in lung cancer.